← 18 Aug 2026 · All rebalances
Short-term Top 10 — Health Care — 24 Aug 2026
The ten as they stood on 24 Aug 2026. Scores, pillars and reasons are the ones recorded that day; nothing here is recomputed. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100.
The short-term score is a published weighted sum of percentile ranks, rebalanced every Monday. A list is a published formula and its output, not a recommendation. Method version 3.
Get this list's changes by email
Who entered, who left, and the reason — with the score moves behind it.
Informational only — not financial advice. The daily email has not started yet — subscribing now puts you on the list for the first one. Unsubscribe in one click.
The ten
| # | Company | Why it was here | Sector | Score |
|---|---|---|---|---|
| 1 | Merck & Co. (MRK) | Volume and participation 94th: trading volume is about normal versus its 30-day average.Volume and participation 94th: trading volume is about normal versus its 30-day average; catalysts 90th: the analyst consensus rating has improved toward "buy" since the prior reading; weakest is setup 38th: day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months). |
Health Care | 72.1 |
| 2 | HINGE HEALTH INC CLASS A (HNGE) | Volume and participation 97th: it gapped 14.9% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed.Volume and participation 97th: it gapped 14.9% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; catalysts 78th: open-market insider buys in 90 days 42, analysts have raised their average price target by 1.3% since the prior reading; weakest is setup 46th: no Elliott-wave labelling currently fits its swings. Its short interest was not measured, so no short-interest deduction applies. |
Health Care | 71.6 |
| 3 | ZENAS BIOPHARMA INC (ZBIO) | Setup 92nd: no fresh 20-day breakout up or down.Setup 92nd: no fresh 20-day breakout up or down; catalysts 77th: analysts have raised their average price target by 8.0% since the prior reading; weakest is momentum 50th: MACD momentum is negative. It is heavily shorted, but it also meets the short-squeeze screen, so no deduction applies. |
Health Care | 71.3 |
| 4 | GLAUKOS CORP (GKOS) | Trend 87th: a strong uptrend, with buyers in control.Trend 87th: a strong uptrend, with buyers in control; catalysts 77th: open-market insider buys in 90 days 27, analysts have raised their average price target by 1.8% since the prior reading; weakest is setup 48th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 3% of it. |
Health Care | 70.2 |
| 5 | IMMUNOME INC (IMNM) | Catalysts 91st: open-market insider buys in 90 days 30, the analyst consensus rating has improved toward "buy" since the prior reading.Catalysts 91st: open-market insider buys in 90 days 30, the analyst consensus rating has improved toward "buy" since the prior reading; trend 83rd: a strong uptrend, with buyers in control; weakest is setup 46th: day-to-day price swings are unusually wide versus its own recent history (wider than about 84% of the past ~6 months). It is heavily shorted, but it also meets the short-squeeze screen, so no deduction applies. |
Health Care | 69.6 |
| 6 | DEFINIUM THERAPEUTICS INC (DFTX) | Catalysts 90th: analysts have raised their average price target by 12.2% since the prior reading.Catalysts 90th: analysts have raised their average price target by 12.2% since the prior reading; volume and participation 77th: it gapped 16.1% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is momentum 53rd: MACD momentum is negative. |
Health Care | 69.5 |
| 7 | Revolution Medicines (RVMD) | Trend 81st: a strong uptrend, with buyers in control.Trend 81st: a strong uptrend, with buyers in control; catalysts 73rd: open-market insider buys in 90 days 25, analysts have raised their average price target by 0.6% since the prior reading; weakest is setup 47th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 2% of it. |
Health Care | 68.2 |
| 8 | KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) | Trend 88th: a "golden cross" — its 50-day average is above its 200-day.Trend 88th: a "golden cross" — its 50-day average is above its 200-day; catalysts 61st: open-market insider buys in 90 days 31, the analyst consensus rating is unchanged since the prior reading; weakest is setup 58th: over the past year its closes ranged, and it has retraced only a small part of its move over the past year — 3% of it. Its short interest was not measured, so no short-interest deduction applies. |
Health Care | 66.4 |
| 9 | Moderna (MRNA) | Catalysts 96th: analysts have raised their average price target by 75.7% since the prior reading.Catalysts 96th: analysts have raised their average price target by 75.7% since the prior reading; trend 80th: it is trading 100.2% above its 50-day average, the short-term trend line; weakest is setup 49th: day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months). Its score is docked 5 points for short interest in the heaviest tenth of the field. |
Health Care | 66.0 |
| 10 | NUVATION BIO INC CLASS A (NUVB) | Trend 71st: it is trading 14.0% above its 50-day average, the short-term trend line.Trend 71st: it is trading 14.0% above its 50-day average, the short-term trend line; setup 70th: no Elliott-wave labelling currently fits its swings; weakest is catalysts 58th: the analyst consensus rating has softened toward "sell" since the prior reading. It is heavily shorted, but it also meets the short-squeeze screen, so no deduction applies. |
Health Care | 66.0 |
Entered on 24 Aug 2026
Merck & Co. (MRK) — Entered 24 Aug 2026: score 72.1, rank 1 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
ZENAS BIOPHARMA INC (ZBIO) — Entered 24 Aug 2026: score 71.3, rank 3 (vs 18 Aug 2026).
GLAUKOS CORP (GKOS) — Entered 24 Aug 2026: score 70.2, rank 4 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
Revolution Medicines (RVMD) — Entered 24 Aug 2026: score 68.2, rank 7 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) — Entered 24 Aug 2026: score 66.4, rank 8 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
Moderna (MRNA) — Entered 24 Aug 2026: score 66.0, rank 9 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
NUVATION BIO INC CLASS A (NUVB) — Entered 24 Aug 2026: score 66.0, rank 10 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version).
Left on 24 Aug 2026
Agilent Technologies (A) — Left 24 Aug 2026: score 62.5, rank 30 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
BridgeBio Pharma, Inc. (BBIO) — Left 24 Aug 2026: score 52.9, rank 105 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
CELLDEX THERAPEUTICS INC (CLDX) — Left 24 Aug 2026: score 55.5, rank 86 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
Encompass Health (EHC) — Left 24 Aug 2026: score 58.5, rank 49 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
EDGEWISE THERAPEUTICS INC (EWTX) — Left 24 Aug 2026: score 64.3, rank 17 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
MINIMED INC (MMED) — Left 24 Aug 2026: score 61.3, rank 38 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
Veeva Systems (VEEV) — Left 24 Aug 2026: score 62.7, rank 28 (not compared with 18 Aug 2026 — those rows were scored under method version 1, this pass under 3, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
See every rebalance of this list →
Informational only — NOT financial advice.